Saturday, 26 September 2026
Saturday, 26 September 2026
- In brief
- 1Bowel cancer in people under 50 has risen about 2% a year since the 1990s, and excess weight explains only 20 of every 100 extra cases
- 2A vaccine built from one patient's tumour
- 3How a per-patient vaccine is made
- 4The size of the benefit is still unknown
- 5Guinea worm: ten cases left in the world
- 6The worm is hiding in dogs
- 7A chatbot matched group therapy in a trial
- 8Across 39 trials, chatbots help a little
- 9The weak spot is people stopping
- 10Bystander CPR in South Korea more than doubled
- 11Qatar's cardiac arrest survival doubled
- 12CPR helped men more than women in Japan
- 13Children who drown survive resuscitation more often
- 14Singapore tests CPR with a live video link
- 15Fit men die suddenly less often
- 16Heat lowers blood pressure by a few points
- 17A sauna works the heart like a walk
- 18Scabies: the cream beat the pill in French homes
- 19In Turkey, the better scabies drug cost two days' pay
- 20Pill and cheap lotion cure scabies equally
- 21Restless legs: the old first-line drugs demoted
- 22Iron is the first thing to check in restless legs
- 23Restless legs in bowel disease, and untreated in Mexico
- 24Tattoo ink ends up in the lymph nodes
- 25Tattoos and cancer: two answers
- 26Inks still break the EU's limits
- 27Congo's clinics report outbreaks by phone
26 Sept · Mind & body · In brief
Mind & body · Saturday, 26 September 2026
Mind & body, in brief
27 stories · 63 sources
Swipe up for the day in brief ↑Scroll down for the day in brief ↓
What is moving · 1 of 4
Guidelines moving before the cause is found
US bowel cancer screening now starts at 45, five years earlier, because the cases were there.
What is moving · 2 of 4
Help arriving before a doctor does
In South Korea 30.3% of cardiac arrests now get CPR from a passer-by, up from 12.9% ten years ago.
What is moving · 3 of 4
Phones stepping into care
An AI chat platform matched face-to-face group therapy in a trial of 995 students in Israel.
What is moving · 4 of 4
Old treatments wearing out
Permethrin cream, the first choice for scabies, fails more often, and Turkish children needed a second drug.
27 stories
11 sources
Mind & body, in brief
- 7Mayo Clinic Q&A: Why are younger people being diagnosed with colorectal cancer?
- 21Progress Toward Eradication of Dracunculiasis (Guinea Worm Disease) - Worldwide, January 2024-June 2025
- 25Efficacy of a Conversational AI Agent for Psychiatric Symptoms and Digital Therapeutic Alliance: A Randomized Clinical Trial
- 36Trends in the Bystander Cardiopulmonary Resuscitation, 2014-2024
- 40Enhanced community first responder support system: protocol of a randomized trial to improve bystander cardiopulmonary resuscitation quality for out-of-hospital cardiac arrest patients
- 43Oral ivermectin versus 5% permethrin cream to treat scabies in index cases and household members: cluster randomised clinical trial
- 44Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies
- 45Efficacy of combination therapy with oral Ivermectin and topical permethrin versus permethrin monotherapy in pediatric patients with persistent scabies: a propensity scoreadjusted observational study
- 47Restless Legs Syndrome and Periodic Limb Movements
- 58Does tattoo exposure increase the risk of cutaneous melanoma? A population-based case-control study
- 62Evaluating the performance of digital surveillance for epidemic-prone diseases in Kwango Province, Democratic Republic of Congo
Bowel cancer in people under 50 has risen about 2% a year since the 1990s, and excess weight explains only 20 of every 100 extra cases
Swipe up for the story ↑Scroll down for the story ↓
Colorectal cancer became the leading cause of cancer death among Americans under 50 in 2023, up from fifth place in 1990, the American Cancer Society reported in January.
deaths in that age group fell over the same years, and East Asia has the highest rate
more than 900,000 people died of it that year, the second-biggest cancer killer
Who is involved
The American Cancer Society
the US charity that counts the country's cancers; its January report in JAMA put colorectal cancer first among cancer deaths under 50
Who is involved
Andrea Cercek
a cancer doctor who runs the young-onset bowel cancer centre at Memorial Sloan Kettering in New York; she says a 22-year-old's polyp must have started at age 10
Why it matters
Watch whether the gut-bacteria and childhood-exposure studies now under way can explain the 80 extra cases in every 100 that excess weight does not.
What's really going on
Bowel cancer in people under 50 has risen about 2% a year since the 1990s, and after thirty years of counting nobody can say why.
What's really going on
Excess weight explains about 20 of every 100 extra cases in England, and the United States lowered its screening age to 45 because the cases were there, not because the cause was found.
Why it works on people
The BBC opens on Bradley Coombes, who died at 23 after 18 months of symptoms; one named young man makes a rise of 2% a year feel like an epidemic, when one young person in 1,000 a year gets any cancer against one in 100 of the old.
Who pays
People under 45 with bowel symptoms
They do not qualify for screening, often see several doctors before a diagnosis, and 60% to 70% are found with advanced disease.
Nobody knows yet
What is causing bowel cancer to rise in the young.
The English analysis found 80 of every 100 extra cases unexplained after weight; sweetened drinks, ultra-processed food, PFAS chemicals, antibiotics, pollution, gut bacteria and weedkillers are all suggested and none is shown.
Nobody knows yet
Whether gut bacteria are a cause or a bystander.
One study linked the E. coli toxin colibactin to colon cancer in younger patients; there is no test for a healthy microbiome and no way yet to say which factor triggers a tumour.
Nobody knows yet
Whether young people's tumours are more aggressive or just found later.
In Qatar, tumours in patients aged 45 and under were more often poorly differentiated and more often advanced, yet five-year survival was the same as in older patients.
Good news
Deaths from cancer among Americans under 50 fell by 44% between 1990 and 2023.
The short version
That's the story in short.
The whole story has 12 more parts.
or swipe up for the next storyor scroll on for the next story ↓
The whole story, in 12 parts ↓
Part 1 of 12 · Who else is involved
The Institute of Cancer Research and Imperial College London
the two London research bodies whose analysis found 11 cancers rising in young people in England
Part 1 of 12 · Who else is involved
John Marshall
head of clinical research at Georgetown University's cancer centre in the US; thirty years ago none of his bowel cancer patients were under 50, now almost half are
Part 2 of 12
Cases in under-50s have climbed about 2% a year since the 1990s, and 60% to 70% are found at an advanced stage.
Part 3 of 12
In March the society said cases in 20-to-49-year-olds are rising 3% a year, and that 45% of this year's diagnoses will be in people under 65, up from 27% in 1995.
Part 4 of 12
In England, 11 cancers are rising in people in their 20s, 30s and 40s, while smoking, drinking, exercise, red meat and fibre all got better or stayed flat over the same years.
Part 5 of 12
The only trend that matched the rise was excess weight, and it explains about 20 of every 100 extra bowel cancers; the other 80 are unexplained.
Part 6 of 12
Across three European cohorts with 1,369 early cases, higher body weight raised men's risk by a third per 5 BMI points, smoking by a quarter and alcohol by 15%, while exercise cut it by 29%.
Part 7 of 12
Rates have risen with each generation born since the 1960s, which points to something in daily life that changed around then.
Part 8 of 12
Up to a fifth of patients carry an inherited fault such as Lynch syndrome; about 80% of cases have no genetic explanation.
Part 9 of 12
Doctors now suspect the gut's bacteria; one study linked colibactin, a DNA-damaging toxin made by some E. coli, to colon cancer in younger patients.
Part 10 of 12
A polyp normally takes about ten years to become a cancer, so a 22-year-old's tumour would have started at about age 10.
Part 11 of 12
US screening now starts at 45 instead of 50; most countries start somewhere in the 40s or early 50s.
Part 12 of 12
People below the screening age often see several doctors before a diagnosis, and bleeding gets put down to piles.
10 sources
Bowel cancer in people under 50 has risen about 2% a year since the 1990s, and excess weight explains only 20 of every 100 extra cases
- 1Colon cancer is killing more young people in the U.S. than any other cancer
- 2Colorectal Cancer: Why Are Almost 50% of Cases Occurring Earlier?
- 311 cancers on the rise in young people - scientists find first clue why it's happening
- 4Scientists search the microbiome for clues to the rise in colorectal cancers
- 5A prospective investigation of early-onset colorectal cancer risk factors - pooled analysis of three large-scale European cohorts
- 6Global Burden of Colorectal Cancer in Adolescents and Young Adults From 1990 to 2021: A Systematic Analysis of the Global Burden of Disease Study 2021
- 7Mayo Clinic Q&A: Why are younger people being diagnosed with colorectal cancer?
- 8Colorectal cancer isn't the only gastrointestinal cancer rising in young adults
- 9Young-onset versus late-onset colorectal cancer: clinicopathological features and survival outcome: a decade-long analysis from a middle Eastern tertiary center
- 10Colorectal cancer
The full story
Bowel cancer in people under 50 has risen about 2% a year since the 1990s, and excess weight explains only 20 of every 100 extra cases
Colorectal cancer became the leading cause of cancer death among Americans under 50 in 2023, up from fifth place in 1990, the American Cancer Society reported in January.
Cases in under-50s have climbed about 2% a year since the 1990s, and 60% to 70% are found at an advanced stage.
In March the society said cases in 20-to-49-year-olds are rising 3% a year, and that 45% of this year's diagnoses will be in people under 65, up from 27% in 1995.
In England, 11 cancers are rising in people in their 20s, 30s and 40s, while smoking, drinking, exercise, red meat and fibre all got better or stayed flat over the same years.
The only trend that matched the rise was excess weight, and it explains about 20 of every 100 extra bowel cancers; the other 80 are unexplained.
Across three European cohorts with 1,369 early cases, higher body weight raised men's risk by a third per 5 BMI points, smoking by a quarter and alcohol by 15%, while exercise cut it by 29%.
Rates have risen with each generation born since the 1960s, which points to something in daily life that changed around then.
Up to a fifth of patients carry an inherited fault such as Lynch syndrome; about 80% of cases have no genetic explanation.
Doctors now suspect the gut's bacteria; one study linked colibactin, a DNA-damaging toxin made by some E. coli, to colon cancer in younger patients.
A polyp normally takes about ten years to become a cancer, so a 22-year-old's tumour would have started at about age 10.
US screening now starts at 45 instead of 50; most countries start somewhere in the 40s or early 50s.
People below the screening age often see several doctors before a diagnosis, and bleeding gets put down to piles.
Why it matters. Watch whether the gut-bacteria and childhood-exposure studies now under way can explain the 80 extra cases in every 100 that excess weight does not.
A vaccine built from one patient's tumour
Swipe up for the story ↑Scroll down for the story ↓
On 19 August Merck and Moderna said their personalised melanoma vaccine, intismeran, met the main goal of a final-stage trial.
The trial enrolled more than 1,000 people whose high-risk melanoma had been cut out; all got the immune drug Keytruda and some also got the vaccine.
Those who got both went longer without the cancer returning and were slower to see it spread to other organs.
Each dose is made from the DNA of that patient's own tumour, so no two patients get the same vaccine.
It is the first mRNA cancer treatment to succeed in a late-stage trial.
Why it matters
Melanoma is the deadliest skin cancer; once it spreads, five-year survival can fall to between 16% and 35%.
Why it matters
The same companies are testing the same idea in lung, bladder and kidney cancer.
7 sources
A vaccine built from one patient's tumour
- 11Landmark trial shows mRNA therapy significantly cuts the odds of recurrent skin cancer
- 12Personalised mRNA therapy reduces risk of melanoma returning in Phase 3 trial
- 13Vaccine breakthrough stops cancer returning in trial
- 14Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
- 18mRNA Vaccines in Melanoma Immunotherapy - A Narrative Review
- 19Daily briefing: Personalized mRNA vaccine shows promise for cancer
- 20Melanoma treatment in the era of nanotechnology and precision medicine
The full story
A vaccine built from one patient's tumour
On 19 August Merck and Moderna said their personalised melanoma vaccine, intismeran, met the main goal of a final-stage trial.
Why it matters. Melanoma is the deadliest skin cancer; once it spreads, five-year survival can fall to between 16% and 35%.
How a per-patient vaccine is made
Swipe up for the story ↑Scroll down for the story ↓
Scientists take a piece of the removed tumour and sequence its DNA to find mutations that exist only in that cancer.
Software then picks the mutated proteins, called neoantigens, and writes them into an mRNA strand the immune system can learn from.
Earlier cancer vaccines aimed at proteins that healthy cells also carry, and the body's tolerance for its own proteins blunted them.
Of 442 melanoma vaccine trials counted up to August 2025, only 6.1% reached phase 3 and 22.9% were stopped early.
Why it matters
Neoantigens skip the tolerance problem because they are not in any healthy cell.
Why it matters
Twenty years of vaccines aimed at shared tumour proteins produced few real responses in patients with advanced cancer.
5 sources
How a per-patient vaccine is made
- 11Landmark trial shows mRNA therapy significantly cuts the odds of recurrent skin cancer
- 12Personalised mRNA therapy reduces risk of melanoma returning in Phase 3 trial
- 13Vaccine breakthrough stops cancer returning in trial
- 16Developing neoantigen cancer vaccines: where are we now?
- 17Melanoma vaccines: current R&D landscape, translational hurdles, and future outlook - a perspective drawn from 442 clinical trials
The full story
How a per-patient vaccine is made
Scientists take a piece of the removed tumour and sequence its DNA to find mutations that exist only in that cancer.
Why it matters. Neoantigens skip the tolerance problem because they are not in any healthy cell.
The size of the benefit is still unknown
Swipe up for the story ↑Scroll down for the story ↓
The companies announced the result in a press release and have not published the data.
The UK coordinating doctor, Heather Shaw of UCLH, said the size of the benefit is not yet known and that full results come at the ESMO cancer congress in October.
Cancer Research UK said the interim data still needs to be fully reviewed.
The vaccine still needs approval from regulators, and in May the US regulator refused a different melanoma treatment that had promising trial results.
Why it matters
Shares in Moderna and Merck surged on the announcement, before anyone outside the companies had seen the numbers.
Who gains
Moderna and Merck
Their shares surged on a press release, weeks before any data is shown to other doctors.
Nobody knows yet
How much the melanoma vaccine helps.
Merck and Moderna announced that the trial met its goal without releasing the data; the size of the benefit comes in October and no peer-reviewed paper exists.
4 sources
The size of the benefit is still unknown
- 11Landmark trial shows mRNA therapy significantly cuts the odds of recurrent skin cancer
- 12Personalised mRNA therapy reduces risk of melanoma returning in Phase 3 trial
- 13Vaccine breakthrough stops cancer returning in trial
- 15Moderna's new mRNA melanoma jab is making headlines, but experts urge caution
The full story
The size of the benefit is still unknown
The companies announced the result in a press release and have not published the data.
Why it matters. Shares in Moderna and Merck surged on the announcement, before anyone outside the companies had seen the numbers.
Guinea worm: ten cases left in the world
Swipe up for the story ↑Scroll down for the story ↓
The Carter Center said at the end of January that ten people caught Guinea worm disease in 2025, in South Sudan, Chad and Ethiopia, down from 15 in 2024.
In 1986 about 3.5 million people a year in 21 countries were infected.
The worm is swallowed as a larva in pond water, grows for about a year, then burns its way out through the skin.
There is no drug and no vaccine; the fall came from cloth filters, treating ponds and keeping cases away from water.
Why it matters
About 100 million infections are estimated to have been prevented.
Good news
In 1986 about 3.5 million people a year caught Guinea worm disease. In 2025 ten people did, and no drug or vaccine was ever made for it.
The full story
Guinea worm: ten cases left in the world
The Carter Center said at the end of January that ten people caught Guinea worm disease in 2025, in South Sudan, Chad and Ethiopia, down from 15 in 2024.
Why it matters. About 100 million infections are estimated to have been prevented.
The worm is hiding in dogs
Swipe up for the story ↑Scroll down for the story ↓
Eradication has stalled on animals: 664 infected animals were reported in 2024, mostly dogs in Cameroon and Chad, and about 700 in 2025.
A dog or a person carries the worm for 10 to 14 months with no sign before it emerges.
Villages now tether dogs during the transmission season and pay cash rewards for reported worms.
Researchers testing a blood test found one antigen, DUF148, picked up 76.6% of hidden infections in Chadian dogs, but it also reacted to other worms.
Since 2023 the world counts as eradicated only when no worm emerges in people or animals for three years.
Why it matters
Cameroon was certified worm-free in 2007 and got the worm back from Chad in 2019, so a country is only safe while its neighbours' dogs are.
How it works
The cause and the illness can be years apart
How it works
A polyp takes ten years to become a cancer, so the cause is found by counting thousands of people by birth year, not by asking one patient.
How it works · step 1 of 5
Something gets into the body: a gut toxin in childhood, tattoo ink, a worm larva in pond water
How it works · step 2 of 5
For months or years there is no sign at all
How it works · step 3 of 5
The illness appears long after, and the doctor sees only the illness
How it works · step 4 of 5
No single patient can connect the two, so the link is found by counting thousands by birth year
How it works · step 5 of 5
The rule then changes years after the exposure began: a screening age, an ink limit, a filter
The twist
By the time a bowel cancer shows, the cause has been gone for ten years.
The twist
Nobody who treats the patient can see it, so the cause has to be found by counting thousands of people by the year they were born.
The picture
How long each of today's stories had to wait between the cause and the sign: a year for a worm, ten for a polyp, and 31 years to count the heart deaths of 1,089 men in Kuopio.
Seen the same day
the ink arrives at about 24 and stays for life, so any cancer it caused would show decades later and only in a count of thousands
Seen the same day
a dog carries the worm for 10 to 14 months with no sign, so the eradication programme now needs a blood test for the silent stage
Seen the same day
the trial met its goal, but how big the benefit is will only be known after patients are followed for years
Seen the same day
1,089 men were measured in the 1980s and counted for 31 years before fitness and heart deaths could be linked
The catch
A count by birth year can show that something changed around 1960 without saying what it was, and obesity, plastics, processed food and gut bacteria all changed at once.
The whole
A doctor sees one patient. A patient feels one body.
The whole
The pattern shows only in a registry of millions, and almost nobody in it will ever read it.
Who gains
Village volunteers in Chad and Cameroon
Cash rewards for reporting a confirmed worm, in place since 2014, pay for the surveillance that finds the last cases.
Who pays
Dog owners along the Chari river in Chad and Cameroon
They tether their dogs for the transmission season, with 79% compliance in Cameroon, so the worm cannot reach the water.
Nobody knows yet
Whether Guinea worm can be eradicated while dogs carry it.
About 700 animal infections were found in 2025, mostly dogs in Chad and Cameroon; the blood test for the silent stage catches 76.6% and reacts to other worms too.
3 sources
The worm is hiding in dogs
The full story
The worm is hiding in dogs
Eradication has stalled on animals: 664 infected animals were reported in 2024, mostly dogs in Cameroon and Chad, and about 700 in 2025.
Why it matters. Cameroon was certified worm-free in 2007 and got the worm back from Chad in 2019, so a country is only safe while its neighbours' dogs are.
A chatbot matched group therapy in a trial
Swipe up for the story ↑Scroll down for the story ↓
A trial in Israel randomly assigned 995 university students with psychological distress to 12 weeks of an AI conversation platform, face-to-face group therapy, or a waiting list.
Published in April 2026, it found the chatbot group's anxiety fell more than the group-therapy group's, by about 2 points on a 21-point scale, and depression fell more than in the waiting-list group.
Post-traumatic stress symptoms did not differ between the groups.
Why it matters
About one in eight people worldwide has a mental disorder and only a quarter of those who need care get it, the authors write.
1 source
A chatbot matched group therapy in a trial
The full story
A chatbot matched group therapy in a trial
A trial in Israel randomly assigned 995 university students with psychological distress to 12 weeks of an AI conversation platform, face-to-face group therapy, or a waiting list.
Why it matters. About one in eight people worldwide has a mental disorder and only a quarter of those who need care get it, the authors write.
Across 39 trials, chatbots help a little
Swipe up for the story ↑Scroll down for the story ↓
A meta-analysis in npj Digital Medicine pooled 39 randomised trials of mental-health chatbots published from 2017 to October 2025.
Across 7,401 people the chatbots cut depressive symptoms by a small-to-moderate amount, an effect size of 0.31, and anxiety by 0.28.
The effect on depression was larger in people who were clinically depressed than in healthy volunteers.
A separate review of 31 trials in 15-to-39-year-olds, covering 29,637 people, found similar sizes and judged the newest generative chatbots' results inconclusive.
Why it matters
In Asia, eight trials with 921 people found a benefit for depression but none for anxiety or stress.
Who gains
Makers of mental-health chatbots such as Woebot and Wysa
A meta-analysis of 39 trials now backs a small benefit, and the reviews call the bots cheap to scale where therapists are short.
4 sources
Across 39 trials, chatbots help a little
- 26Systematic review and meta analysis of chatbots in the management of depressive and anxiety symptoms
- 27The Effectiveness of AI Chatbots in Alleviating Mental Distress and Promoting Health Behaviors Among Adolescents and Young Adults: Systematic Review and Meta-Analysis
- 28Clinical Efficacy, Therapeutic Mechanisms, and Implementation Features of Cognitive Behavioral TherapyBased Chatbots for Depression and Anxiety: Narrative Review
- 29Chatbot interventions for improving mental health among people in Asia: a systematic review and meta-analysis of randomised controlled trials
The full story
Across 39 trials, chatbots help a little
A meta-analysis in npj Digital Medicine pooled 39 randomised trials of mental-health chatbots published from 2017 to October 2025.
Why it matters. In Asia, eight trials with 921 people found a benefit for depression but none for anxiety or stress.
The weak spot is people stopping
Swipe up for the story ↑Scroll down for the story ↓
In a review of nine chatbot studies in college students, up to 61% of participants dropped out.
Many commercial mental-health apps keep fewer than 4% of users active after the first month, the Israeli trial's authors note.
Repetitive content and technical problems were the main reasons young people quit.
Why it matters
Most of these trials lasted two to eight weeks, so nobody knows whether the benefit holds.
Nobody knows yet
Whether chatbot benefits last.
The Israeli trial ran 12 weeks with a three-month follow-up, and most trials in the reviews ran two to eight weeks.
4 sources
The weak spot is people stopping
- 25Efficacy of a Conversational AI Agent for Psychiatric Symptoms and Digital Therapeutic Alliance: A Randomized Clinical Trial
- 27The Effectiveness of AI Chatbots in Alleviating Mental Distress and Promoting Health Behaviors Among Adolescents and Young Adults: Systematic Review and Meta-Analysis
- 28Clinical Efficacy, Therapeutic Mechanisms, and Implementation Features of Cognitive Behavioral TherapyBased Chatbots for Depression and Anxiety: Narrative Review
- 30Effectiveness of artificial intelligence chatbots on mental health & well-being in college students: a rapid systematic review
The full story
The weak spot is people stopping
In a review of nine chatbot studies in college students, up to 61% of participants dropped out.
Why it matters. Most of these trials lasted two to eight weeks, so nobody knows whether the benefit holds.
Bystander CPR in South Korea more than doubled
Swipe up for the story ↑Scroll down for the story ↓
The Korea Disease Control and Prevention Agency reported in January that 30.3% of people who had a sudden cardiac arrest outside hospital in 2024 got CPR from a bystander, up from 12.9% in 2014.
That is 2.3 times the rate of ten years earlier.
Bystander means anyone who is not an on-duty paramedic or medical professional.
Why it matters
Survival after a cardiac arrest depends on the minutes before an ambulance arrives, and only a bystander is there for them.
Good news
In South Korea, the share of people whose hearts stopped outside hospital and who got CPR from a passer-by rose from 12.9% in 2014 to 30.3% in 2024.
2 sources
Bystander CPR in South Korea more than doubled
The full story
Bystander CPR in South Korea more than doubled
The Korea Disease Control and Prevention Agency reported in January that 30.3% of people who had a sudden cardiac arrest outside hospital in 2024 got CPR from a bystander, up from 12.9% in 2014.
Why it matters. Survival after a cardiac arrest depends on the minutes before an ambulance arrives, and only a bystander is there for them.
Qatar's cardiac arrest survival doubled
Swipe up for the story ↑Scroll down for the story ↓
Qatar's national registry followed 1,238 adults whose hearts stopped outside hospital and whom paramedics tried to revive.
17.8% survived to leave hospital and 13.5% did so with their brain largely intact, against 8.1% and 5.4% in the country's previous count.
Most arrests happened at home, 61.8% were witnessed and 42.4% got bystander CPR.
Being witnessed, getting a shock before hospital, and having a blocked artery opened within 24 hours each predicted survival.
Why it matters
Survival to discharge after cardiac arrest is 7% to 11% in most places and has barely moved in 30 to 40 years.
Good news
In Qatar, survival after a cardiac arrest outside hospital rose from 8.1% to 17.8% between one national count and the next.
1 source
Qatar's cardiac arrest survival doubled
The full story
Qatar's cardiac arrest survival doubled
Qatar's national registry followed 1,238 adults whose hearts stopped outside hospital and whom paramedics tried to revive.
Why it matters. Survival to discharge after cardiac arrest is 7% to 11% in most places and has barely moved in 30 to 40 years.
CPR helped men more than women in Japan
Swipe up for the story ↑Scroll down for the story ↓
Among 9,081 adults treated for cardiac arrest at 42 Japanese emergency centres from 2019 to 2021, 61.9% were men.
Bystander CPR went with higher 30-day survival in both sexes: 11.0% against 4.5% in men and 5.4% against 3.4% in women.
After adjustment the link stayed strong in men but was not statistically significant in women, and the difference between the sexes was itself significant.
The authors say the reasons need investigating.
Why it matters
The authors say the difference needs explaining, and that bystander CPR should be delivered equally to both sexes in the meantime.
Who pays
Women whose hearts stop outside hospital
In Japan bystander CPR lifted survival less for women, 5.4% against 3.4%, than for men, 11.0% against 4.5%.
Nobody knows yet
Why bystander CPR helped men more than women in Japan.
The survival gap was statistically significant and the authors offer no mechanism.
1 source
CPR helped men more than women in Japan
The full story
CPR helped men more than women in Japan
Among 9,081 adults treated for cardiac arrest at 42 Japanese emergency centres from 2019 to 2021, 61.9% were men.
Why it matters. The authors say the difference needs explaining, and that bystander CPR should be delivered equally to both sexes in the meantime.
Children who drown survive resuscitation more often
Swipe up for the story ↑Scroll down for the story ↓
Germany's resuscitation registry holds 68,719 cardiac arrests from 2013 to 2023; 316 were caused by drowning, half of them in June, July and August.
Drowning patients were younger, median 50 against 72, and colder, with a body temperature of 31.1 degrees C against 35.8 at the scene.
Overall survival was no different from other arrests.
Why it matters
Drowning is one of the five leading causes of death for 1-to-14-year-olds in Europe, and most of it is preventable.
1 source
Children who drown survive resuscitation more often
The full story
Children who drown survive resuscitation more often
Germany's resuscitation registry holds 68,719 cardiac arrests from 2013 to 2023; 316 were caused by drowning, half of them in June, July and August.
Why it matters. Drowning is one of the five leading causes of death for 1-to-14-year-olds in Europe, and most of it is preventable.
Singapore tests CPR with a live video link
Swipe up for the story ↑Scroll down for the story ↓
Singapore has trained 17,800 volunteers and given them a credit-card-sized device that shows the depth and speed of their chest compressions.
Even with it, only 36% delivered good-quality CPR in a simulation, and many said they feared pressing hard enough to do harm.
A registered randomised trial will now stream the card's data and a video call to the ambulance dispatcher, who can coach the volunteer as it happens.
The control group gets the usual voice-only instructions.
Why it matters
Good CPR raises survival 3.9 times over poor CPR, the protocol says, and over half of volunteers in one survey had ignored an alert.
1 source
Singapore tests CPR with a live video link
The full story
Singapore tests CPR with a live video link
Singapore has trained 17,800 volunteers and given them a credit-card-sized device that shows the depth and speed of their chest compressions.
Why it matters. Good CPR raises survival 3.9 times over poor CPR, the protocol says, and over half of volunteers in one survey had ignored an alert.
Fit men die suddenly less often
Swipe up for the story ↑Scroll down for the story ↓
A review of cohort studies finds that four or more hours a week of moderate-to-vigorous activity, or good measured fitness, goes with a 40% to 50% lower risk of sudden cardiac death.
Sudden cardiac death is an unexpected death from the heart within about an hour of symptoms, and it causes 15% to 20% of all deaths worldwide.
In Kuopio, Finland, 1,089 men measured in the 1980s were followed for a median of 31.2 years.
Fitter men died of heart disease less often, and fitness divided by waist size predicted death better than either measure alone.
Why it matters
No randomised trial can assign people to be unfit for decades, so the link rests on counting, and the reviewers say the causal question is still open.
How it works
1,089 men were measured in the 1980s and counted for 31 years before fitness and heart deaths could be linked
The idea, in story 6: The cause and the illness can be years apart →The full story
Fit men die suddenly less often
A review of cohort studies finds that four or more hours a week of moderate-to-vigorous activity, or good measured fitness, goes with a 40% to 50% lower risk of sudden cardiac death.
Why it matters. No randomised trial can assign people to be unfit for decades, so the link rests on counting, and the reviewers say the causal question is still open.
Heat lowers blood pressure by a few points
Swipe up for the story ↑Scroll down for the story ↓
A meta-analysis of 51 studies of passive heating, in saunas and hot baths, found a single session lowered average blood pressure by about 5 mmHg.
Repeated sessions lowered the top number by about 5 and the bottom number by about 3.
A second meta-analysis of 20 hot-water immersion studies found one session raised the heart rate by 28 beats a minute and cut the bottom number by 5 mmHg, but called the overall benefit inconclusive.
Why it matters
The reviewers say the size of the effect was much the same whether people were healthy or ill, young or old.
2 sources
Heat lowers blood pressure by a few points
The full story
Heat lowers blood pressure by a few points
A meta-analysis of 51 studies of passive heating, in saunas and hot baths, found a single session lowered average blood pressure by about 5 mmHg.
Why it matters. The reviewers say the size of the effect was much the same whether people were healthy or ill, young or old.
A sauna works the heart like a walk
Swipe up for the story ↑Scroll down for the story ↓
A Finnish sauna runs at 80 to 100 degrees C and pushes the heart rate to 120 to 150 beats a minute, the level of moderate exercise.
Blood flow to the skin can rise to 7 to 8 litres a minute.
A 2025 review of sauna studies in heart disease found the observational studies consistent and the randomised trials mixed, and asked for standard protocols and longer trials.
In 28 healthy young women, three ten-minute sauna rounds raised the top blood-pressure number in the first round and lowered it across the rounds.
Why it matters
The review says the strongest case is for people who cannot exercise, and that the trials do not yet prove it.
Nobody knows yet
Whether saunas prevent heart disease or just go with it.
The observational studies agree and the randomised trials are mixed, the 2025 review says.
3 sources
A sauna works the heart like a walk
- 32The Role of Sauna Bathing in Ischemic Heart Disease: A Narrative Review of Therapeutic Potential, Physiological Mechanisms, and Emerging Clinical Applications
- 34Thermal stress: an untapped potential in rehabilitation? An opinion paper on Finnish sauna and whole-body cryostimulation
- 35Acute Finnish sauna heating and cold water immersion effects on cardiovascular dynamic response in normotensive women
The full story
A sauna works the heart like a walk
A Finnish sauna runs at 80 to 100 degrees C and pushes the heart rate to 120 to 150 beats a minute, the level of moderate exercise.
Why it matters. The review says the strongest case is for people who cannot exercise, and that the trials do not yet prove it.
Scabies: the cream beat the pill in French homes
Swipe up for the story ↑Scroll down for the story ↓
Scabies is a mite that burrows into the skin; about 207 million people have it at any time.
In 28 French hospitals, 289 households with a confirmed case were randomly given either ivermectin pills or permethrin cream for everyone in the home, on day 0 and day 10.
At day 28, 88.5% of cream households were cured against 71.8% of pill households.
A second French trial gave 132 adults with severe scabies a double dose of ivermectin or the standard dose, both with cream; cure was 75% and 82%, so the higher dose did no better.
Why it matters
Ivermectin is easier to give to a whole village, which is why mass treatment programmes use it; these trials say the cream, applied head to toe, still cures more.
3 sources
Scabies: the cream beat the pill in French homes
- 43Oral ivermectin versus 5% permethrin cream to treat scabies in index cases and household members: cluster randomised clinical trial
- 44Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies
- 46Efficacy and safety of oral ivermectin versus benzyl benzoate for the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials
The full story
Scabies: the cream beat the pill in French homes
Scabies is a mite that burrows into the skin; about 207 million people have it at any time.
Why it matters. Ivermectin is easier to give to a whole village, which is why mass treatment programmes use it; these trials say the cream, applied head to toe, still cures more.
In Turkey, the better scabies drug cost two days' pay
Swipe up for the story ↑Scroll down for the story ↓
Turkish doctors followed 230 children whose scabies had survived at least one course of permethrin cream.
Families chose, after cost counselling, between adding two doses of ivermectin or continuing the cream alone.
Adding the pills cut the time to halve the itch from 9.8 days to 7.2, raised the four-week cure rate from 66.0% to 83.8% and halved recurrence at three months.
Until March 2023 ivermectin was sold only in 20-tablet import packs costing 28% to 37% of a month's minimum wage; a generic cut that to 5% to 7%.
Why it matters
The same four tablets cost under 1% of the minimum wage in Australia and under 0.3% in India, so which drug a child gets depends on where the child lives.
Who gains
The Turkish maker of generic ivermectin
A local generic in 10-tablet packs cut a family's cost from up to 37% of a month's minimum wage to 5% to 7%.
Who pays
Families in Turkey with a child whose scabies came back
Before March 2023 the pills came only in 20-tablet import packs costing up to 37% of a month's minimum wage.
1 source
In Turkey, the better scabies drug cost two days' pay
The full story
In Turkey, the better scabies drug cost two days' pay
Turkish doctors followed 230 children whose scabies had survived at least one course of permethrin cream.
Why it matters. The same four tablets cost under 1% of the minimum wage in Australia and under 0.3% in India, so which drug a child gets depends on where the child lives.
Pill and cheap lotion cure scabies equally
Swipe up for the story ↑Scroll down for the story ↓
A meta-analysis of ten randomised trials with 1,105 patients compared oral ivermectin with benzyl benzoate lotion, an old and cheap treatment.
Cure rates were the same at one week, at two to four weeks and after four weeks.
The lotion caused far more burning and stinging; ivermectin had about a quarter as many side effects.
Scabies was added to the WHO's list of neglected tropical diseases in 2017, and permethrin, the usual first choice, is failing more often.
Why it matters
Where permethrin fails or is unaffordable, the cheap lotion works as well as the pill, at the price of stinging.
1 source
Pill and cheap lotion cure scabies equally
The full story
Pill and cheap lotion cure scabies equally
A meta-analysis of ten randomised trials with 1,105 patients compared oral ivermectin with benzyl benzoate lotion, an old and cheap treatment.
Why it matters. Where permethrin fails or is unaffordable, the cheap lotion works as well as the pill, at the price of stinging.
Restless legs: the old first-line drugs demoted
Swipe up for the story ↑Scroll down for the story ↓
Restless legs syndrome is an urge to move the legs in the evening that spoils sleep; it affects 2% to 5% of people badly enough to matter.
For years the first drugs given were dopamine agonists, the class used in Parkinson's disease.
In 2025 the American Academy of Sleep Medicine downgraded their long-term use because of augmentation, in which the drug makes symptoms start earlier in the day, get stronger and spread to other parts of the body.
Gabapentin-type drugs are now the mainstay, and most patients on the old drugs end up escalating doses and stopping all medication within ten years.
Why it matters
A drug that worked at first and then made the illness worse was the standard treatment.
Who pays
Restless-legs patients who started dopamine drugs years ago
Augmentation makes symptoms come earlier and spread, and most escalate doses and stop all medication within ten years.
4 sources
Restless legs: the old first-line drugs demoted
- 47Restless Legs Syndrome and Periodic Limb Movements
- 48Neuromodulation for Restless Legs Syndrome: A Systematic Review and Mechanistic Considerations for Spinal Cord Stimulation
- 49Sleep Related Movement Disorders: What's New and Changing Clinical Practice
- 63Treatment of restless legs syndrome by acupuncture combined with medicine based on pathophysiological mechanism
The full story
Restless legs: the old first-line drugs demoted
Restless legs syndrome is an urge to move the legs in the evening that spoils sleep; it affects 2% to 5% of people badly enough to matter.
Why it matters. A drug that worked at first and then made the illness worse was the standard treatment.
Iron is the first thing to check in restless legs
Swipe up for the story ↑Scroll down for the story ↓
Iron shortage is found in 25% to 40% of people with restless legs, and topping it up is the first-line treatment.
Guidelines say to give iron when ferritin, the blood's iron-store reading, is 75 micrograms per litre or below, and moderate evidence supports iron by drip.
A 2025 meta-analysis of 31 studies found iron by drip beat iron by mouth in kidney disease, bowel disease and cancer, but found no difference for restless legs.
Where iron is not the cause, treatment depends on severity and on whether another illness, such as kidney failure, is behind it.
Why it matters
More than 160 genetic risk spots have been found and no single gene explains the illness.
Who gains
Makers of iron drips such as ferric carboxymaltose
Restless-legs guidelines now put iron ahead of the old dopamine drugs, though a 2025 meta-analysis found no advantage of the drip over iron tablets for the syndrome.
6 sources
Iron is the first thing to check in restless legs
- 47Restless Legs Syndrome and Periodic Limb Movements
- 48Neuromodulation for Restless Legs Syndrome: A Systematic Review and Mechanistic Considerations for Spinal Cord Stimulation
- 49Sleep Related Movement Disorders: What's New and Changing Clinical Practice
- 50Efficacy of oral vs. intravenous iron for the treatment of iron deficiency anemia in different conditions: A systematic review and meta-analysis
- 53Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
- 54Restless Legs Syndrome (RLS): Symptoms & Treatment
The full story
Iron is the first thing to check in restless legs
Iron shortage is found in 25% to 40% of people with restless legs, and topping it up is the first-line treatment.
Why it matters. More than 160 genetic risk spots have been found and no single gene explains the illness.
Restless legs in bowel disease, and untreated in Mexico
Swipe up for the story ↑Scroll down for the story ↓
A meta-analysis found restless legs in about 15% of people with inflammatory bowel disease, against about 3% of adults in general.
Bowel disease causes iron loss and long-running inflammation, both linked to the syndrome.
In Latin America, a survey of 69,830 Mexican women found 15.6% had the syndrome, 54.5% of them with frequent symptoms, and only 18.1% were treated.
Iron testing is limited in many countries and the newer first-line drugs are hard to get, so dopamine agonists and sedatives are still widely used.
Why it matters
The treatment a person gets depends on which drugs a country's pharmacies stock.
3 sources
Restless legs in bowel disease, and untreated in Mexico
- 51Restless legs syndrome and inflammatory bowel disease: A systematic review and meta-analysis
- 52The AASM Guidelines for the Treatment of Restless Legs Syndrome (RLS) in the Context of Latin America
- 63Treatment of restless legs syndrome by acupuncture combined with medicine based on pathophysiological mechanism
The full story
Restless legs in bowel disease, and untreated in Mexico
A meta-analysis found restless legs in about 15% of people with inflammatory bowel disease, against about 3% of adults in general.
Why it matters. The treatment a person gets depends on which drugs a country's pharmacies stock.
Tattoo ink ends up in the lymph nodes
Swipe up for the story ↑Scroll down for the story ↓
Researchers tattooed the footpads of mice with black, red and green ink and watched it drain through the lymph vessels within ten minutes.
Within a day it had piled up in the nearest lymph node, and after two months the node was still inflamed.
Human lymph-node biopsies from tattooed patients showed the same pattern of ink.
In the mice, ink at the injection site lowered the antibody response to an mRNA COVID vaccine and raised it to an inactivated flu vaccine.
This is a mouse result; nobody has tested vaccine responses in tattooed people.
Why it matters
About 29% of Swedish adults have a tattoo, and most got the first one between 18 and 35, so the ink sits in the body for most of a life.
3 sources
Tattoo ink ends up in the lymph nodes
- 55Tattoo ink induces inflammation in the draining lymph node and alters the immune response to vaccination
- 58Does tattoo exposure increase the risk of cutaneous melanoma? A population-based case-control study
- 61Tattoos in the general Swedish population: prevalence, determinants, and exposure characteristics
The full story
Tattoo ink ends up in the lymph nodes
Researchers tattooed the footpads of mice with black, red and green ink and watched it drain through the lymph vessels within ten minutes.
Why it matters. About 29% of Swedish adults have a tattoo, and most got the first one between 18 and 35, so the ink sits in the body for most of a life.
Tattoos and cancer: two answers
Swipe up for the story ↑Scroll down for the story ↓
A Swedish case-control study of people diagnosed at 20 to 60 found tattooed people had a 29% higher rate of melanoma, and it was not higher for bigger tattoos.
A Dutch nationwide registry found 94 melanomas on tattoos among 142,492 melanomas from 1991 to 2023 and concluded tattoos are unlikely to raise the risk.
For lymphoma, a meta-analysis of four studies with 17,941 people found no link, an odds ratio of 1.01.
An earlier Swedish study had found a link with lymphoma, and a Danish twin study a link with skin cancer.
Why it matters
Neither yes nor no is settled; the studies count different things, and people get the ink young and carry it for decades.
Nobody knows yet
Whether tattoos raise cancer risk.
A Swedish case-control study found melanoma 29% more common in tattooed people; a Dutch registry of 142,492 melanomas found no sign of it; a meta-analysis found no lymphoma link while an earlier Swedish study did.
4 sources
Tattoos and cancer: two answers
- 56Investigating the potential association between tattoos and lymphoma: an exploratory systematic review and meta-analysis
- 57Incidence of Tattoo-Associated Melanoma in the Netherlands (1991-2023): A Nationwide Registry Study
- 58Does tattoo exposure increase the risk of cutaneous melanoma? A population-based case-control study
- 60Tattoo inks as a long-term exposure and why primary care should care
The full story
Tattoos and cancer: two answers
A Swedish case-control study of people diagnosed at 20 to 60 found tattooed people had a 29% higher rate of melanoma, and it was not higher for bigger tattoos.
Why it matters. Neither yes nor no is settled; the studies count different things, and people get the ink young and carry it for decades.
Inks still break the EU's limits
Swipe up for the story ↑Scroll down for the story ↓
EU rules limiting 4,000 chemicals in tattoo ink took effect in January 2022.
A study of 41 inks sold in the EU afterwards found nickel over the limit in 24, arsenic in 20, chromium in 16 and lead in 5; mercury was absent.
Nickel reached a lifetime cancer risk above one in 10,000 in several products.
Tattooed Swedes are more often smokers, with odds 2.86 times higher, and lower on income and education.
Why it matters
Whatever the inks do, they do it more to people who already carry more health risks.
4 sources
Inks still break the EU's limits
- 58Does tattoo exposure increase the risk of cutaneous melanoma? A population-based case-control study
- 59Heavy Metal Content in Tattoo and Permanent Makeup Inks and European Standards - Is There Still a Health Risk?
- 60Tattoo inks as a long-term exposure and why primary care should care
- 61Tattoos in the general Swedish population: prevalence, determinants, and exposure characteristics
The full story
Inks still break the EU's limits
EU rules limiting 4,000 chemicals in tattoo ink took effect in January 2022.
Why it matters. Whatever the inks do, they do it more to people who already carry more health risks.
Congo's clinics report outbreaks by phone
Swipe up for the story ↑Scroll down for the story ↓
Kwango Province in the Democratic Republic of Congo piloted a digital case-reporting system, SORMAS, from July 2022 to December 2024.
Where health workers at clinics entered cases themselves, 46% of reports arrived within a day; where data went to a district office for entry, 5% did.
2,950 cases of epidemic-prone diseases were logged.
Why it matters
The pilot shows that who does the typing decides how fast a case is known.
1 source
Congo's clinics report outbreaks by phone
The full story
Congo's clinics report outbreaks by phone
Kwango Province in the Democratic Republic of Congo piloted a digital case-reporting system, SORMAS, from July 2022 to December 2024.
Why it matters. The pilot shows that who does the typing decides how fast a case is known.
That's the whole Mind & body day.
27 stories, 63 sources.